Pyrazoloacridine
- Generic Name
- Pyrazoloacridine
- Drug Type
- Small Molecule
- Chemical Formula
- C19H21N5O3
- CAS Number
- 99009-20-8
- Unique Ingredient Identifier
- L24XJN68OW
- Background
Pyrazoloacridine has been used in trials studying the treatment of Lung Cancer, Liver Cancer, Breast Cancer, Melanoma (Skin), and Metastatic Cancer, among others.
Chemotherapy in Treating Patients With Unresectable Primary or Metastatic Kidney Cancer
- First Posted Date
- 2004-09-14
- Last Posted Date
- 2012-02-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT00003714
Pyrazoloacridine in Treating Women With Metastatic Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2004-08-11
- Last Posted Date
- 2012-03-12
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT00002585
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Pyrazoloacridine in Treating Patients With Advanced Non-small Cell Lung Cancer
- First Posted Date
- 2004-06-10
- Last Posted Date
- 2013-04-29
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT00002656
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Pyrazoloacridine in Treating Women With Refractory Metastatic Breast Cancer
- Conditions
- Breast Cancer
- Locations
- 🇺🇸
Central Baptist Hospital, Lexington, Kentucky, United States
🇺🇸Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States
🇺🇸Grant/Riverside Methodist Hospitals, Columbus, Ohio, United States
Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma
- Conditions
- Intraocular MelanomaMelanoma (Skin)
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Pyrazoloacridine and Stem Cell or Bone Marrow Transplantation in Treating Young Patients With High-Risk Neuroblastoma
- Conditions
- Disseminated NeuroblastomaRecurrent Neuroblastoma
- Interventions
- Biological: filgrastimProcedure: autologous bone marrow transplantationProcedure: peripheral blood stem cell transplantationOther: laboratory biomarker analysisOther: pharmacological study
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2013-04-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT00053950
- Locations
- 🇺🇸
New Approaches to Neuroblastoma Treatment (NANT), Los Angeles, California, United States
Pyrazoloacridine Plus Carboplatin in Treating Patients With Recurrent Glioma
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT00005976
- Locations
- 🇺🇸
CentraCare Health Plaza, Saint Cloud, Minnesota, United States
🇺🇸Medcenter One Health System, Bismarck, North Dakota, United States
🇺🇸Altru Cancer Center, Grand Forks, North Dakota, United States
Pyrazoloacridine Followed by Radiation Therapy in Treating Adults With Newly Diagnosed Supratentorial Glioblastoma Multiforme
- Conditions
- Brain and Central Nervous System Tumors
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.